Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: FDA Starts November With A Bang

Nov 02 2018

• By Michael Cipriano, Sue Sutter, Brenda Sandburg, and Bridget Silverman

Keeping Track Feature image

Related Content

Shionogi’s <em>Osphena</em> May Offer Safer Alternative To Estrogen

Feb 26 2013

Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab

Apr 29 2018

The New 180 Days? Humira Biosimilar Deals Give Amgen 150-Day Jump On Samsung

Apr 06 2018

Trevena's IV Opioid Not Quite 'Ready for Primetime,' US FDA Panel Concludes

Oct 12 2018

AbbVie's Fourth Humira Patent Settlement Allows Sandoz Biosimilar US Entry Eight Months After Amgen

Oct 12 2018

Trevena's Intravenous Opioid Will Face Difficult US FDA Advisory Committee

Oct 10 2018

Celltrion’s Biosimilar Rituximab Brings Indication Carve Outs To US FDA Panel Review

Sep 13 2018

Controversial Dengue Drug Among Six Products To Get EMA Thumbs Up

Oct 19 2018

Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too

Dec 05 2016

Humira Biosimilar Settlement Could Be Model For Other Disputes

Sep 29 2017

Novo Nordisk's Victoza Adds CV Benefit Claim, But Not For Primary Prevention

Aug 28 2017

Apotex Moves To Block Coherus' Neulasta Biosimilar; Asks FDA To Require Patient Studies

May 01 2017

Amgen Alleges 'Massive Conspiracy' By Employees Who Joined Coherus And KBI

Mar 08 2017

Biosimilar Litigation Trends: Settlements, Declaratory Judgment Rejections, Congressional Intervention

Aug 12 2018

US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals

May 29 2018

Zavante Targets Resistant Urinary Infections With I.V. Version Of Existing Drug

Apr 06 2017

Mylan Is First To Clear US Neulasta Biosimilar Hurdle; At-Risk Launch May Not Be Risky

Jun 05 2018

Brakes On Sanofi’s Dengvaxia Prospects Amid WHO-SAGE Screening Advice?

Apr 25 2018

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

May 22 2018

Pfizer On Reorganizing, M&A And Investing In Internal R&D

Aug 01 2018

Merck's Keytruda Monotherapy May Get Stuck With Small Role In First-line Lung Cancer

Jun 04 2018

Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown

Jul 12 2018

Nabriva Gains New CEO And Near-Market Antibiotic, Claims Leadership Role

Jul 25 2018

EMA ‘Yes’ For Pegfilgrastim Biosimilars Spells End For Neulasta’s EU Stronghold

Jul 27 2018

Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA

Jun 12 2017

Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last

Jun 24 2018

Related Companies

Viatris Inc.

Apotex Inc.

Novartis AG

Boehringer Ingelheim GmbH

Samsung Bioepis Co., Ltd.

Sanofi

Sanofi

Zambon Company S.p.A.

Shionogi & Co. Ltd.

Celltrion, Inc.

Talphera, Inc.

Pfizer Inc.

Coherus Oncology, Inc.

Amgen, Inc.

Novartis AG

AbbVie Inc.

TherapeuticsMD Inc.

Merck & Co., Inc.

Johnson & Johnson

Sanofi

Trevena Inc.

Novo Nordisk A/S

Acer Therapeutics Inc.

Additional Topics

United States Approvals Drug Review Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window